Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas

Molecular Oncology

Volumn 9, Issue 4, 2015, Pages 758-771

  Sandhu, V ^a,c   Bowitz Lothe, I M ^a   Labori, K J ^a   Lingjaerde O C ^b   Buanes, T ^a,d   Dalsgaard, A M ^a   Skrede, M L ^a   Hamfjord, J ^a   Haaland, T ^a   Eide, T J ^a,d   Borresen Dale A L ^a,d   Ikdahl, T ^a   Kure, E H ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Histological subtypes; Molecular expression profiling; Pancreatic cancer; Periampullary adenocarcinoma; Prognostic markers; Signaling pathways

Indexed keywords

ATM PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; GLUCOSE TRANSPORTER 4; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MESSENGER RNA; MICRORNA; MICRORNA 127 3P; MICRORNA 193B; MICRORNA 196B; MICRORNA 335; MICRORNA 365; MICRORNA 377; MICRORNA 382; MICRORNA 424; MICRORNA 455 3P; MICRORNA 497; MICRORNA 592; MICRORNA 654 3P; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PUMA PROTEIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; COMPARATIVE STUDY; DNA REPAIR; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PERIAMPULLARY ADENOCARCINOMA; PRIORITY JOURNAL; RB1 GENE; RECURRENCE FREE SURVIVAL; UPREGULATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; INTESTINE TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VATER PAPILLA; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; BIOMARKERS, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER;

EID: 84926408623     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.12.002     Document Type: Article

References (49)

1. Albores-Saavedra J., Simpson K., Dancer Y.J., Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann. Diagn. Pathol. 2007, 11:3-9.
2. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.Roy. Stat. Soc. B. 1995, 57:289-300.
3. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., Wilkinson K.A., Banchereau R., Skinner J., Wilkinson R.J., Quinn C., Blankenship D., Dhawan R., Cush J.J., Mejias A., Ramilo O., Kon O.M., Pascual V., Banchereau J., Chaussabel D., O'Garra A. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
4. WHO Classification of Tumors of the Digestive System 2010, International Agency for Research on Cancer. fourth Ed. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
5. Chang W.W., Lin R.J., Yu J., Chang W.Y., Fu C.H., Lai A.C., Yu J.C., Yu A.L. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res. BCR. 2013, 15:R39.
6. Chen C., Zhang Y., Zhang L., Weakley S.M., Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer. J.Cell. Mol. Med. 2011, 15:14-23.
7. Chen Z., Jin Y., Yu D., Wang A., Mahjabeen I., Wang C., Liu X., Zhou X. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol. 2012, 48:686-691.
8. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cel. Biol. 2008, 9:616-627.
9. Collisson E.A., Sadanandam A., Olson P., Gibb W.J., Truitt M., Gu S., Cooc J., Weinkle J., Kim G.E., Jakkula L., Feiler H.S., Ko A.H., Olshen A.B., Danenberg K.L., Tempero M.A., Spellman P.T., Hanahan D., Gray J.W. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 2011, 17:500-503.
10. Conkrite K., Sundby M., Mukai S., Thomson J.M., Mu D., Hammond S.M., MacPherson D. miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev. 2011, 25:1734-1745.
11. De Jong M.C., Tsai S., Cameron J.L., Wolfgang C.L., Hirose K., van Vledder M.G., Eckhauser F., Herman J.M., Edil B.H., Choti M.A., Schulick R.D., Pawlik T.M. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J.Surg. Oncol. 2010, 102:256-263.
12. Dicitore A., Caraglia M., Gaudenzi G., Manfredi G., Amato B., Mari D., Persani L., Arra C., Vitale G. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-gamma (PPAR-gamma): at the cross-road of pancreatic cancer cell proliferation. Biochim. Biophys. Acta 2014, 1845:42-52.
13. Donahue T.R., Tran L.M., Hill R., Li Y., Kovochich A., Calvopina J.H., Patel S.G., Wu N., Hindoyan A., Farrell J.J., Li X., Dawson D.W., Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin. Cancer Res. official J. Am. Assoc. Cancer Res. 2012, 18:1352-1363.
14. Dweep H., Sticht C., Pandey P., Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J.Biomed. Inform. 2011, 44:839-847.
15. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., Hornik K., Hothorn T., Huber W., Iacus S., Irizarry R., Leisch F., Li C., Maechler M., Rossini A.J., Sawitzki G., Smith C., Smyth G., Tierney L., Yang J.Y., Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
16. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J.Nutr. 2001, 131:3109S-3120S.
17. Hamfjord J., Stangeland A.M., Skrede M.L., Tveit K.M., Ikdahl T., Kure E.H. Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations. Diagn. Mol. Pathol. Am. J. Surg. Pathol. part B 2011, 20:158-165.
18. Hamilton M.P., Rajapakshe K., Hartig S.M., Reva B., McLellan M.D., Kandoth C., Ding L., Zack T.I., Gunaratne P.H., Wheeler D.A., Coarfa C., McGuire S.E. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat. Commun. 2013, 4:2730.
19. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
20. Kimura W., Futakawa N., Yamagata S., Wada Y., Kuroda A., Muto T., Esaki Y. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn. J. Cancer Res. Gann 1994, 85:161-166.
21. Kristiansen G., Jacob J., Buckendahl A.C., Grutzmann R., Alldinger I., Sipos B., Kloppel G., Bahra M., Langrehr J.M., Neuhaus P., Dietel M., Pilarsky C. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin. Cancer Res. official J. Am. Assoc. Cancer Res. 2006, 12:6444-6451.
22. Lopez-Romero P. Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library. BMC genomics 2011, 12:64.
23. Maloof J.N., Whangbo J., Harris J.M., Jongeward G.D., Kenyon C. A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Development 1999, 126:37-49.
24. Milosevic J., Pandit K., Magister M., Rabinovich E., Ellwanger D.C., Yu G., Vuga L.J., Weksler B., Benos P.V., Gibson K.F., McMillan M., Kahn M., Kaminski N. Profibrotic role of miR-154 in pulmonary fibrosis. Am. J. Respir. Cel. Mol. Biol. 2012, 47:879-887.
25. MSigDb: (version v4.0 revised on May 31, 2013). http://www.broadinstitute.org/gsea/msigdb/index.jsp.
26. Murphy B.L., Obad S., Bihannic L., Ayrault O., Zindy F., Kauppinen S., Roussel M.F. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 2013, 73:7068-7078.
27. Neoptolemos J.P., Moore M.J., Cox T.F., Valle J.W., Palmer D.H., McDonald A.C., Carter R., Tebbutt N.C., Dervenis C., Smith D., Glimelius B., Charnley R.M., Lacaine F., Scarfe A.G., Middleton M.R., Anthoney A., Ghaneh P., Halloran C.M., Lerch M.M., Olah A., Rawcliffe C.L., Verbeke C.S., Campbell F., Buchler M.W. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA: J. Am. Med. Assoc. 2012, 308:147-156. European Study Group for Pancreatic, C.
28. Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., Padbury R., Moore M.J., Gallinger S., Mariette C., Wente M.N., Izbicki J.R., Friess H., Lerch M.M., Dervenis C., Olah A., Butturini G., Doi R., Lind P.A., Smith D., Valle J.W., Palmer D.H., Buckels J.A., Thompson J., McKay C.J., Rawcliffe C.L., Buchler M.W. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA: J. Am. Med. Assoc. 2010, 304:1073-1081. European Study Group for Pancreatic, C.
29. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Buchler M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New Engl. J. Med. 2004, 350:1200-1210. European Study Group for Pancreatic, C.
30. Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zulke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA: J. Am. Med. Assoc. 2013, 310:1473-1481.
31. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA: J. Am. Med. Assoc. 2007, 297:267-277.
32. Olive V., Bennett M.J., Walker J.C., Ma C., Jiang I., Cordon-Cardo C., Li Q.J., Lowe S.W., Hannon G.J., He L. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009, 23:2839-2849.
33. Overman M.J., Zhang J., Kopetz S., Davies M., Zhi-Qin J., Stemke-Hale K., Rummele P., Pilarsky C., Grutzmann R., Hamilton S., Hwang R., Abbruzzese J.L., Varadhachary G., Broom B., Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PloS One 2013, 8:e65144.
34. Pichiorri F., Suh S.S., Rocci A., De Luca L., Taccioli C., Santhanam R., Zhou W., Benson D.M., Hofmainster C., Alder H., Garofalo M., Di Leva G., Volinia S., Lin H.J., Perrotti D., Kuehl M., Aqeilan R.I., Palumbo A., Croce C.M. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer cell 2010, 18:367-381.
35. Saldanha A.J. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004, 20:3246-3248.
36. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer cell 2002, 2:103-112.
37. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. Article3.
38. Smyth G.K., Michaud J., Scott H.S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005, 21:2067-2075.
39. Sobin L.H., Gospodarowicz M.K., Wittekind Ch., International Union against Cancer Classification of Malignant Tumorus 2009, Wiley-BlackWell, Hoboken, NJ. seventh ed.
40. Subramani R., Lopez-Valdez R., Arumugam A., Nandy S., Boopalan T., Lakshmanaswamy R. Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PloS One 2014, 9:e97016.
41. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. United States America 2005, 102:15545-15550.
42. Therneau Terry M., Grambsch Patricia M. Modeling Survival Data: Extending the Cox Model 2000, Springer, New York.
43. Thomas J.K., Kim M.S., Balakrishnan L., Nanjappa V., Raju R., Marimuthu A., Radhakrishnan A., Muthusamy B., Khan A.A., Sakamuri S., Tankala S.G., Singal M., Nair B., Sirdeshmukh R., Chatterjee A., Prasad T.S., Maitra A., Gowda H., Hruban R.H., Pandey A. Pancreatic Cancer Database: an integrative resource for pancreatic cancer. Cancer Biol. Ther. 2014, 15.
44. Westgaard A., Pomianowska E., Clausen O.P., Gladhaug I.P. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?. Ann. Surg. Oncol. 2013, 20:430-439.
45. Westgaard A., Tafjord S., Farstad I.N., Cvancarova M., Eide T.J., Mathisen O., Clausen O.P., Gladhaug I.P. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC cancer 2008, 8:170.
46. Winter J.M., Brennan M.F., Tang L.H., D'Angelica M.I., Dematteo R.P., Fong Y., Klimstra D.S., Jarnagin W.R., Allen P.J. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann. Surg. Oncol. 2012, 19:169-175.
47. Yoshizawa K., Cioca D.P., Kawa S., Tanaka E., Kiyosawa K. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 2002, 95:2243-2251.
48. Zhang Y., Morris J.P.t., Yan W., Schofield H.K., Gurney A., Simeone D.M., Millar S.E., Hoey T., Hebrok M., Pasca di Magliano M. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013, 73:4909-4922.
49. Zou L. Single- and double-stranded DNA: building a trigger of ATR-mediated DNA damage response. Genes Dev. 2007, 21:879-885.